<?php

use Twig\Environment;
use Twig\Error\LoaderError;
use Twig\Error\RuntimeError;
use Twig\Extension\SandboxExtension;
use Twig\Markup;
use Twig\Sandbox\SecurityError;
use Twig\Sandbox\SecurityNotAllowedTagError;
use Twig\Sandbox\SecurityNotAllowedFilterError;
use Twig\Sandbox\SecurityNotAllowedFunctionError;
use Twig\Source;
use Twig\Template;

/* themes/custom/entyviohcp/templates/content/node--gemini-i-entyvio-vs-placebo--full.html.twig */
class __TwigTemplate_e40e5ab602f8add5cd06808151b5e328d79065e559bc7a419671e9160fa12314 extends \Twig\Template
{
    private $source;
    private $macros = [];

    public function __construct(Environment $env)
    {
        parent::__construct($env);

        $this->source = $this->getSourceContext();

        $this->parent = false;

        $this->blocks = [
        ];
        $this->sandbox = $this->env->getExtension('\Twig\Extension\SandboxExtension');
        $this->checkSecurity();
    }

    protected function doDisplay(array $context, array $blocks = [])
    {
        $macros = $this->macros;
        // line 1
        echo "<div data-page-id=\"GeminiTrial\" data-page-category=\"ClinicalEfficacy\" class=\"page-content gemini-trial-content\" >
  <div id=\"bodyy\" class=\"article gemini-trial-article\">
    <div id=\"hero\">
      <div>
        <picture>
          <source media=\"screen and (max-width: 959px)\" srcset=\"";
        // line 6
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 6, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 6, $this->source)), "html", null, true);
        echo "/images/hero/mobile-gemini-varsity-ed.png\">
          <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"";
        // line 7
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 7, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 7, $this->source)), "html", null, true);
        echo "/images/hero/desktop-gemini-varsity-ed.png\">
          <img src=\"";
        // line 8
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 8, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 8, $this->source)), "html", null, true);
        echo "/images/hero/desktop-gemini-varsity-ed.png\" alt=\"Patient.\">
        </picture>
        <article>
          <div>
            <h1>
              GEMINI I<br>
              <strong>UC Trials <br class=\"special-breakpoint\">I &amp; II</strong>
            </h1>
          </div>
          <div>
            <h2>Clinical <br>Response &amp; <br><strong>Long‐Term <br>Data</strong></h2>
          </div>
        </article>
        <picture>
          <source media=\"screen and (max-width: 959px)\" srcset=\"";
        // line 22
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 22, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 22, $this->source)), "html", null, true);
        echo "/images/hero/mobile-gemini-i-varsity-dosing-tricia.png\">
          <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"";
        // line 23
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 23, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 23, $this->source)), "html", null, true);
        echo "/images/hero/desktop-gemini-i-varsity-dosing-tricia.png\">
          <img src=\"";
        // line 24
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 24, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 24, $this->source)), "html", null, true);
        echo "/images/hero/desktop-gemini-i-varsity-dosing-tricia.png\" alt=\"Healthcare professional.\">
        </picture>
      </div>
    </div>
    <div id=\"first_section\">
      <div id=\"indication_bar\" class=\"close\">
        <div>
          <div class=\"section\">
            <h3>For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough or cannot be&nbsp;tolerated.</h3>
          </div>
        </div>
      </div>
      <div>
        <article>
          <div id=\"overview-trial-data\" class=\"overview-trial-data\">
            <h2 class=\"border\">OVERVIEW OF GEMINI&nbsp;I&nbsp;DATA</h2>
            <p class=\"subheading description-below\">UC Trials I and II</p>
            <div class=\"container\">
              <div class=\"flex-container\" data-row=\"\">
                <div class=\"half graph-1\" data-col=\"mobile-12 desktop-6\">
                  <p class=\"end-point-heading\">Primary End Points</p>
                  <div class=\"tile\">
                    <h3>
                      RAPID RESPONSE AT WEEK 6 AND <nobr>LONG-TERM</nobr> REMISSION AT <br class=\"special-breakpoint-3\" data-only=\"desktop\"> WEEK&nbsp;52<sup>1</sup>
                    </h3>
                    <div class=\"image-container side-by-side gemini\">
                      <figure>
                        <picture>
                          <source media=\"screen and (max-width: 959px)\" srcset=\"";
        // line 52
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 52, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 52, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-clinical-remission.png\">
                          <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"";
        // line 53
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 53, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 53, $this->source)), "html", null, true);
        echo "/images/charts/desktop-gemini-clinical-remission.png\">
                          <img src=\"";
        // line 54
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 54, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 54, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-clinical-remission.png\" alt=\"Entyvio® (vedolizumab) ulcerative colitis clinical trial rapid response and long-term remission data.\" title=\"Entyvio® GEMINI I Study Data\">
                        </picture>
                      </figure>
                    </div>
                  </div>
                </div>
                <div class=\"half graph-2 endoscopic-improvement\" data-col=\"mobile-12 desktop-6\">
                  <p class=\"end-point-heading\">Secondary End Points</p>
                  <div class=\"tile\">
                    <h3>
                        RATE OF VISIBLE MUCOSAL IMPROVEMENT AT WEEK 6 AND <br class=\"special-breakpoint-4\" data-only=\"desktop\">WEEK&nbsp;52<sup>1,2‡</sup>
                    </h3>
                    <div class=\"image-container side-by-side gemini\">
                      <figure>
                        <picture>
                          <source media=\"screen and (max-width: 959px)\" srcset=\"";
        // line 69
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 69, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 69, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-endoscopic-improvement.png\">
                          <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"";
        // line 70
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 70, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 70, $this->source)), "html", null, true);
        echo "/images/charts/desktop-gemini-endoscopic-improvement.png\">
                          <img src=\"";
        // line 71
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 71, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 71, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-endoscopic-improvement.png\" alt=\"Entyvio® (vedolizumab) ulcerative colitis GEMINI I clinical trial rate of visible mucosal improvement data.\" title=\"Entyvio® GEMINI I Study Data\">
                        </picture>
                      </figure>
                    </div>
                  </div>
                </div>

                <div class=\"full text-description\">
                  <p class=\"end-point-description\"><strong>Study Design:</strong> Two randomized, double‑blind, placebo‑controlled studies enrolled adult patients with moderately to severely active UC who had failed at least 1 conventional therapy, including corticosteroids or immunomodulators and/or ≥1 anti‑TNFα therapy.<sup>1,2</sup> In UC Trial I, patients were randomized (3:2) to receive Entyvio 300&nbsp;mg or placebo by intravenous infusion at Weeks 0 and 2. In UC Trial II, patients receiving Entyvio who demonstrated clinical response at Week 6 (from UC Trial I or an open-label cohort) were randomized (1:1:1) to receive either Entyvio 300&nbsp;mg every 8&nbsp;weeks, Entyvio 300&nbsp;mg every 4&nbsp;weeks, or placebo every 4&nbsp;weeks.<sup>1</sup> The Entyvio Q4W dosing regimen did not demonstrate additional clinical benefit over the Q8W dosing regimen. The Q4W dosing regimen is not the recommended dosing regimen.</p>
                </div>

                <div class=\"half graph-3\" data-col=\"mobile-12 desktop-6\">
                  <p class=\"end-point-heading\">Secondary End Point</p>
                  <div class=\"tile last-tile\">
                    <h3>CORTICOSTEROID-FREE CLINICAL REMISSION AT WEEK&nbsp;52<sup>1,2§</sup></h3>
                    <div class=\"image-container\">
                      <figure>
                        <picture>
                          <source media=\"screen and (max-width: 959px)\" srcset=\"";
        // line 89
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 89, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 89, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-corticosteroid-free.png\">
                          <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"";
        // line 90
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 90, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 90, $this->source)), "html", null, true);
        echo "/images/charts/desktop-gemini-corticosteroid-free.png\">
                          <img src=\"";
        // line 91
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 91, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 91, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-corticosteroid-free.png\" class=\"solo chart-smaller\" alt=\"Corticosteroid-free remission data in Entyvio® (vedolizumab) ulcerative colitis GEMINI I clinical trials.\" title=\"GEMINI I Study Data\">
                        </picture>
                      </figure>
                    </div>
                  </div>
                </div>
                <div class=\"half button-and-footnotes\" data-col=\"mobile-12 desktop-6\">
                  <div class=\"btn-container\">
                    <a href=\"#study-design\" class=\"btn btn-secondary\">VIEW FULL STUDY DESIGN</a>
                  </div>
                  <p class=\"footnote\">
                    <span class=\"ref\">*</span>
                    <span class=\"text\">Clinical response = reduction in complete Mayo score of ≥3 points and ≥30% from baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point.</span>
                  </p>
                  <p class=\"footnote\">
                    <span class=\"ref\"><sup>†</sup></span>
                    <span class=\"text\">Clinical remission = complete Mayo score of ≤2 points and no individual subscore&nbsp;&gt;1&nbsp;point.</span>
                  </p>
                  <p class=\"footnote\">
                    <span class=\"ref\"><sup>‡</sup></span>
                    <span class=\"text\">Improvement of endoscopic appearance of the mucosa = Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern, mild friability). </span>
                  </p>
                  <p class=\"footnote\">
                    <span class=\"ref\"><sup>§</sup></span>
                    <span class=\"text\">Assessed in the subgroup of patients who were receiving corticosteroids at baseline and who were in clinical response at Week 6 (n=72 for placebo and n=70 for Entyvio Q8W). Corticosteroid-free clinical remission was defined as the proportion of patients in this subgroup who discontinued corticosteroids by Week 52 and were in clinical remission at Week&nbsp;52.</span>
                  </p>
                  <p class=\"footnote acronyms\">
                    <span class=\"text\">CI = confidence interval; Q4W = every 4 weeks; Q8W = every 8 weeks; TNFα = tumor necrosis factor alpha.</span>
                  </p>
                </div>
              </div>
            </div>
          </div>
        </article>
      </div>
    </div>
    <div id=\"second_section\" class=\"move-ahead-header\">
      <div>
        <article>
          <div class=\"move-ahead\">
            <h2 class=\"border-center\"><span>MOVE AHEAD TO <br data-only=\"mobile\">ADDITIONAL DATA</span></h2>
            <div class=\"link-container\" data-row=\"\">
              <div data-col=\"mobile-12 desktop-4\" class=\"anchor-link-container\">
                <a href=\"#rapid-response\">Clinical Response Data</a>
              </div>
              <div data-col=\"mobile-12 desktop-4\" class=\"anchor-link-container\">
                <a href=\"#long-term-data\">Long-Term Data</a>
              </div>
              <div data-col=\"mobile-12 desktop-4\" class=\"anchor-link-container\">
                <a href=\"#study-design\">Study Design</a>
              </div>
            </div>
          </div>
        </article>
      </div>
    </div>
    <div id=\"third_section\">
        <div>
            <article>
                <div id=\"rapid-response\" class=\"clinical-response-rates\">
                    <h2 class=\"banner below-nav\"><span>CLINICAL RESPONSE DATA</span></h2>
                    <p class=\"subheading\">Clinical Response Data</p>
                    <div class=\"container\">
                        <div class=\"accordion-container\">
                            <!-- ACCORDION STARTS -->
                            <div class=\"accordion\">
                                <div class=\"accordion-list\">
                                    <ul class=\"accordion-controls\">
                                        <li class=\"active\">
                                            <div data-empty-button=\"\">
                                                ANTI‑TNFα NAÏVE <em class=\"and\">AND</em> ANTI‑TNFα FAILURE SUBPOPULATIONS
                                            </div>
                                            <p class=\"gotham-medium\">Clinical response* rates—exploratory end&nbsp;point.</p>
                                            <div id=\"clinical_response_rates_content_id_2\" aria-hidden=\"false\">
                                                <div class=\"content\">
                                                    <p class=\"link-below\">At Week 6, in the anti‑TNFα naïve subpopulation, clinical response rates were 53% for those who received Entyvio vs. 26% for those who received placebo. In the anti‑TNFα failure subpopulation, clinical response rates were 39% for those who received Entyvio vs. 21% for those who received placebo.<sup>3</sup></p>
                                                    <p data-only=\"desktop\" class=\"see-text\">Go back to top of page for GEMINI I Primary End Point Data</p>
                                                </div>
                                                <figure class=\"figure-content\">
                                                    <h3>CLINICAL RESPONSE AT WEEK&nbsp;6<sup>3</sup>*</h3>
                                                    <picture>
                                                        <source media=\"screen and (max-width: 959px)\" srcset=\"";
        // line 172
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 172, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 172, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-ccr-no-previous-anti-tnf-a.png\">
                                                        <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"";
        // line 173
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 173, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 173, $this->source)), "html", null, true);
        echo "/images/charts/desktop-gemini-ccr-no-previous-anti-tnf-a.png\">
                                                        <img src=\"";
        // line 174
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 174, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 174, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-ccr-no-previous-anti-tnf-a.png\" class=\"desktop-side-padding\" alt=\"Entyvio® (vedolizumab) ulcerative colitis GEMINI I clinical trials data: response at Week 6 in Anti-TNFα naive and failure subpopulations.\" title=\"GEMINI I Study Data\">
                                                    </picture>
                                                </figure>
                                            </div>
                                        </li>
                                    </ul>
                                    <div class=\"sub-accordion-container\">
                                        <p data-only=\"mobile\" class=\"see-text jump-to\">Go back to top of page for GEMINI I Primary End Point Data</p>
                                        <div class=\"btn-container\">
                                            <a href=\"#study-design\" class=\"btn btn-secondary\">VIEW FULL STUDY DESIGN</a>
                                        </div>
                                        <p class=\"footnote\">
                                            <span class=\"ref\">*</span>
                                            <span class=\"text\">Clinical response = reduction in complete Mayo score of ≥3 points and ≥30% from baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point.</span>
                                        </p>
                                        <p class=\"footnote acronyms\">
                                            <span class=\"text\">CI = confidence interval; TNFα = tumor necrosis factor&nbsp;alpha.</span>
                                        </p>
                                    </div>
                                </div>
                                <div>
                                    <figure class=\"desktop-image\">
                                        <h3>CLINICAL RESPONSE AT WEEK&nbsp;6<sup>3</sup>*</h3>
                                        <picture>
                                            <source media=\"screen and (max-width: 959px)\" srcset=\"";
        // line 198
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 198, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 198, $this->source)), "html", null, true);
        echo "images/charts/mobile-gemini-ccr-no-previous-anti-tnf-a.png\">
                                            <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"";
        // line 199
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 199, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 199, $this->source)), "html", null, true);
        echo "/images/charts/desktop-gemini-ccr-no-previous-anti-tnf-a.png\">
                                            <img src=\"";
        // line 200
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 200, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 200, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-ccr-no-previous-anti-tnf-a.png\" class=\"desktop-side-padding\" alt=\"Entyvio® (vedolizumab) ulcerative colitis GEMINI I clinical trials data: response at Week 6 in Anti-TNFα naive and failure subpopulations.\" title=\"GEMINI I Study Data\">
                                        </picture>
                                    </figure>
                                </div>
                            </div>
                            <!-- ACCORDION ENDS -->
                        </div>
                    </div>
                    <p class=\"subheading\">Clinical Response Measured by Partial Mayo Score<sup>3</sup></p>
                    <div class=\"container\">
                        <div class=\"flex-container\" data-row=\"\">
                            <div class=\"figure-container\" data-col=\"mobile-12 desktop-7\">
                                <figure>
                                    <figcaption>CLINICAL RESPONSE RATES BASED ON PARTIAL MAYO SCORE AT WEEKS 2, 4, AND&nbsp;6<sup>3†</sup></figcaption>
                                    <picture>
                                        <source media=\"screen and (max-width: 959px)\" srcset=\"";
        // line 215
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 215, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 215, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-crr-partial-mayo-score.png\">
                                        <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"";
        // line 216
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 216, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 216, $this->source)), "html", null, true);
        echo "/images/charts/desktop-gemini-crr-partial-mayo-score.png\">
                                        <img src=\"";
        // line 217
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 217, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 217, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-crr-partial-mayo-score.png\" class=\"gemini\" alt=\"Clinical response measured by partial Mayo score in Entyvio® (vedolizumab) clinical trials.\" title=\"GEMINI I Study Data\">
                                    </picture>
                                </figure>
                            </div>
                            <div class=\"copy-container gemini\" data-col=\"mobile-12 desktop-5\">
                                <p class=\"gotham-medium\">Clinical response rates based on partial Mayo&nbsp;score</p>
                                <p class=\"body-copy\">The partial Mayo score is a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and physician’s global assessment), each scored on a scale from 0 to 3 (higher scores indicate greater disease activity). Partial Mayo score is calculated analogously to the complete Mayo score but excludes the sigmoidoscopy subscore.<sup>3</sup></p>
                                <p class=\"body-copy\">Clinical response was defined as a reduction in partial Mayo score of ≥2 points and ≥25% from baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point.<sup>3</sup></p>
                                <div class=\"btn-container\">
                                    <a href=\"#study-design\" class=\"btn btn-secondary gemini\">VIEW FULL STUDY DESIGN</a>
                                </div>
                                <p class=\"footnote\">
                                    <span class=\"ref\"><sup>†</sup></span>
                                    <span class=\"text\">Partial Mayo score and complete Mayo score were highly correlated at baseline and Week 6. Pearson correlation coefficients were 0.95 (95% CI: 0.94, 0.96) and 0.98 (95% CI: 0.97, 0.98) at baseline and Week 6, respectively. When further evaluating the clinical response at Week 6 correlation using kappa statistics, there was also substantial agreement between the 2 scores (0.78 [95% CI: 0.70, 0.86]). </span>
                                </p>
                                <p class=\"footnote acronyms\">
                                    <span class=\"text\">CI = confidence interval.</span>
                                </p>
                                <p class=\"bottom-text jump-to\">
                                    Go back to top of page for GEMINI I Primary End Point Data
                                </p>
                            </div>
                        </div>
                    </div>
                </div>
                <div id=\"long-term-data\" class=\"long-term-data\">
                    <h2 class=\"banner\"><span>LONG-TERM DATA</span></h2>
                    <p class=\"subheading\">Entyvio Offers Long‑Term Remission&nbsp;Data<sup>1</sup></p>
                    <div class=\"container\">
                        <div class=\"accordion-container\">
                            <!-- ACCORDION STARTS -->
                            <div class=\"accordion\">
                                <div class=\"accordion-list\">
                                    <ul class=\"accordion-controls\">
                                        <li class=\"active\">
                                            <div data-empty-button=\"\">
                                                ANTI‑TNFα NAÏVE <em class=\"and\">AND</em> ANTI‑TNFα FAILURE SUBPOPULATIONS
                                            </div>
                                            <p class=\"gotham-medium\">Long-term clinical remission* rates—exploratory end&nbsp;points.</p>
                                            <div id=\"long_term_data_content_id_2\" aria-hidden=\"false\">
                                                <div class=\"content\">
                                                    <p class=\"link-below\">At Week 52, in the anti‑TNFα naïve subpopulation, clinical remission rates were 46% for those who received Entyvio vs. 19% for those who received placebo. In the anti‑TNFα failure subpopulation, clinical remission rates were 37% for those who received Entyvio vs. 5% for those who received placebo.<sup>3</sup></p>
                                                    <p class=\"see-text\" data-only=\"desktop\">Go back to top of page for GEMINI I Primary End Point Data</p>
                                                </div>
                                                <figure class=\"figure-content\">
                                                    <h3>CLINICAL REMISSION AT WEEK&nbsp;52<sup>3</sup>*</h3>
                                                    <picture>
                                                        <source media=\"screen and (max-width: 959px)\" srcset=\"";
        // line 264
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 264, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 264, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-ltr-no-previous-anti-tnf-a.png\">
                                                        <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"";
        // line 265
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 265, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 265, $this->source)), "html", null, true);
        echo "/images/charts/desktop-gemini-ltr-no-previous-anti-tnf-a.png\">
                                                        <img src=\"";
        // line 266
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 266, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 266, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-ltr-no-previous-anti-tnf-a.png\" class=\"desktop-side-padding\" alt=\"Rate of clinical remission at Week 52 Anti-TNFα subpopulations in Entyvio® (vedolizumab) GEMINI I study.\" title=\"GEMINI I Study Data\">
                                                    </picture>
                                                </figure>
                                            </div>
                                        </li>
                                    </ul>
                                    <div class=\"sub-accordion-container\">
                                        <p class=\"see-text no-margin\" data-only=\"mobile\">Go back to top of page for GEMINI I Primary End Point Data</p>
                                        <div class=\"btn-container\">
                                            <a href=\"#study-design\" class=\"btn btn-secondary\">VIEW FULL STUDY DESIGN</a>
                                        </div>
                                        <p class=\"footnote\">
                                            <span class=\"ref\">*</span>
                                            <span class=\"text\">Clinical remission = complete Mayo score of ≤2 points and no individual subscore&nbsp;&gt;1&nbsp;point.</span>
                                        </p>
                                        <p class=\"footnote acronyms\">
                                            <span class=\"text\">CI = confidence interval; Q8W = every 8 weeks; TNFα = tumor necrosis factor&nbsp;alpha.</span>
                                        </p>
                                    </div>
                                </div>
                                <div>
                                    <figure class=\"desktop-image\">
                                        <h3>CLINICAL REMISSION AT WEEK&nbsp;52<sup>3</sup>*</h3>
                                        <picture>
                                            <source media=\"screen and (max-width: 959px)\" srcset=\"";
        // line 290
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 290, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 290, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-ltr-no-previous-anti-tnf-a.png\">
                                            <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"";
        // line 291
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 291, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 291, $this->source)), "html", null, true);
        echo "/images/charts/desktop-gemini-ltr-no-previous-anti-tnf-a.png\">
                                            <img src=\"";
        // line 292
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 292, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 292, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-ltr-no-previous-anti-tnf-a.png\" class=\"desktop-side-padding\" alt=\"Rate of clinical remission at Week 52 Anti-TNFα subpopulations in Entyvio® (vedolizumab) GEMINI I study.\" title=\"GEMINI I Study Data\">
                                        </picture>
                                    </figure>
                                </div>
                            </div>
                            <!-- ACCORDION ENDS -->
                        </div>
                    </div>
                    <p class=\"subheading\">Improvement of Endoscopic Appearance&nbsp;Rates<sup>1</sup></p>
                    <div class=\"container\">
                        <div class=\"accordion-container\">
                            <!-- ACCORDION STARTS -->
                            <div class=\"accordion\">
                                <div class=\"accordion-list\">
                                    <ul class=\"accordion-controls\">
                                        <li class=\"active\">
                                            <div data-empty-button=\"\">
                                                ANTI‑TNFα NAÏVE <em class=\"and\">AND</em> ANTI‑TNFα FAILURE SUBPOPULATIONS
                                            </div>
                                            <p class=\"gotham-medium\">Improvement of the endoscopic appearance of the mucosa<sup>†</sup>—exploratory end points.</p>
                                            <div id=\"double_rate_content_1\" aria-hidden=\"false\">
                                                <div class=\"content\">
                                                    <p>At Week 52, in the anti‑TNFα naïve subpopulation, improvement of the endoscopic appearance of the mucosa rates were 60% for patients who received Entyvio vs. 24% for those who received placebo. In the anti‑TNFα failure subpopulation, improvement of the endoscopic appearance of the mucosa rates were 42% for those who received Entyvio vs. 8% for those who received placebo.<sup>3</sup></p>
                                                    <p data-only=\"desktop\" class=\"see-text\">Go back to top of page for GEMINI I Primary End Point Data</p>
                                                </div>
                                                <figure class=\"figure-content\">
                                                    <h3>IMPROVEMENT OF THE APPEARANCE OF THE MUCOSA AT WEEK 52<sup>3†</sup></h3>
                                                    <picture>
                                                        <source media=\"screen and (max-width: 959px)\" srcset=\"";
        // line 320
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 320, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 320, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-ltr-endo-no-previous-anti-tnf-a.png\">
                                                        <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"";
        // line 321
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 321, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 321, $this->source)), "html", null, true);
        echo "/images/charts/desktop-gemini-ltr-endo-no-previous-anti-tnf-a.png\">
                                                        <img src=\"";
        // line 322
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 322, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 322, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-ltr-endo-no-previous-anti-tnf-a.png\" alt=\"GEMINI I Entyvio® clinical trial Anti-TNFα subpopulation endoscopic subscore data.\" title=\"GEMINI I Study Data\">
                                                    </picture>
                                                </figure>
                                            </div>
                                        </li>
                                    </ul>
                                    <div class=\"sub-accordion-container\">
                                        <p data-only=\"mobile\" class=\"see-text jump-to\">Go back to top of page for GEMINI I Primary End Point Data</p>
                                        <div class=\"btn-container\">
                                            <a href=\"#study-design\" class=\"btn btn-secondary\">VIEW FULL STUDY DESIGN</a>
                                        </div>
                                        <p class=\"footnote\">
                                            <span class=\"ref\"><sup>†</sup></span>
                                            <span class=\"text\">Endoscopic improvement = Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern, mild friability).</span>
                                        </p>
                                        <p class=\"footnote acronyms\">
                                            <span class=\"text\">CI = confidence interval; Q8W = every 8 weeks; TNFα = tumor necrosis factor&nbsp;alpha.</span>
                                        </p>
                                    </div>
                                </div>
                                <div>
                                    <figure class=\"desktop-image\">
                                        <h3>IMPROVEMENT OF THE APPEARANCE OF THE MUCOSA AT WEEK 52<sup>3†</sup></h3>
                                        <picture>
                                            <source media=\"screen and (max-width: 959px)\" srcset=\"";
        // line 346
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 346, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 346, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-ltr-endo-no-previous-anti-tnf-a.png\">
                                            <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"";
        // line 347
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 347, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 347, $this->source)), "html", null, true);
        echo "/images/charts/desktop-gemini-ltr-endo-no-previous-anti-tnf-a.png\">
                                            <img src=\"";
        // line 348
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 348, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 348, $this->source)), "html", null, true);
        echo "/images/charts/mobile-gemini-ltr-endo-no-previous-anti-tnf-a.png\" alt=\"GEMINI I Entyvio® clinical trial Anti-TNFα subpopulation endoscopic subscore data.\" title=\"GEMINI I Study Data\">
                                        </picture>
                                    </figure>
                                </div>
                            </div>
                            <!-- ACCORDION ENDS -->
                        </div>
                    </div>
                </div>
                <div id=\"study-design\" class=\"study-design\">
                    <h2 class=\"banner\"><span>STUDY DESIGN<sup>1-3</sup></span></h2>
                    <p class=\"subheading\">GEMINI I: UC Trials I and II</p>
                    <div class=\"container\">
                        <div class=\"figure-container\">
                            <div class=\"mobile-scroll-container\">
                                <figure>
                                    <img src=\"";
        // line 364
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, ($this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 364, $this->source) . $this->sandbox->ensureToStringAllowed(($context["directory"] ?? null), 364, $this->source)), "html", null, true);
        echo "/images/charts/gemini-trials-study-design.png\" class=\"gemini\" alt=\"GEMINI I study design.\" title=\"GEMINI I Study Design\">
                                </figure>
                            </div>
                            <p class=\"scroll-instruction\" data-only=\"mobile\">Scroll left and right to see more</p>
                        </div>
                        <div class=\"copy-container\">
                            <ul class=\"gemini\" data-bullet=\"primary\">
                                <li>Enrolled adult patients with moderately to severely active UC who had failed at least 1 conventional therapy, including corticosteroids or immunomodulators and/or ≥1 anti‑TNFα&nbsp;therapy<sup>‡</sup></li>
                                <li><span class=\"gotham-medium\">UC Trial I:</span> 2 cohorts with primary end point evaluation at Week&nbsp;6<sup>‡</sup></li>
                                <li><span class=\"gotham-medium\">UC Trial II:</span> Patients receiving Entyvio in cohorts 1 and 2 of UC Trial I who achieved clinical response at Week 6 were randomly assigned to continue receiving Entyvio every 4 or 8 weeks, or placebo every 4&nbsp;weeks, for up to 52&nbsp;weeks<sup>‡</sup></li>
                            </ul>
                            <p class=\"footnote\">
                                <span class=\"ref\">*</span>
                                <span class=\"text\">The Entyvio Q4W dosing regimen did not demonstrate additional clinical benefit over the Q8W dosing regimen. The Q4W dosing regimen is not the recommended dosing&nbsp;regimen.</span>
                            </p>
                            <p class=\"footnote\">
                                <span class=\"ref\"><sup>†</sup></span>
                                <span class=\"text\">Clinical response = reduction in complete Mayo score of ≥3 points and ≥30% from baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1&nbsp;point.</span>
                            </p>
                            <p class=\"footnote\">
                                <span class=\"ref\"><sup>‡</sup></span>
                                <span class=\"text\">Concomitant aminosalicylates, corticosteroids, and immunomodulators were permitted. Corticosteroids were tapered after Week 6; in the United States, immunosuppressants were discontinued after&nbsp;induction.</span>
                            </p>
                            <p class=\"footnote acronyms\">
                                <span class=\"text\">IV = intravenously; Q4W = every 4 weeks; Q8W = every 8 weeks; TNFα = tumor necrosis factor alpha.</span>
                            </p>
                        </div>
                    </div>
                </div>
                <div class=\"interior-bottom-cta\">
                    <div class=\"cta-container\" data-row=\"\">
                        <div class=\"cta-1 cta\" data-col=\"mobile-12 desktop-6\">
                            <p>Entyvio vs. Humira<sup>®</sup>&nbsp;<span class=\"generic\">(adalimumab)</span> Data</p>
                            <a href=\"";
        // line 397
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, $this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 397, $this->source), "html", null, true);
        echo "clinical-efficacy/ulcerative-colitis/varsity-trial\" class=\"btn btn-secondary\">SEE VARSITY STUDY RESULTS</a>
                            <p class=\"footnote\">
                                Humira<sup>®</sup> (AbbVie Inc. North Chicago, IL).<br>
                                For more information related to Humira, please see AbbVie.com.
                            </p>
                        </div>
                        <div class=\"cta-2 cta\" data-col=\"mobile-12 desktop-6\">
                            <p>Entyvio Safety Profile</p>
                            <a href=\"";
        // line 405
        echo $this->extensions['Drupal\Core\Template\TwigExtension']->escapeFilter($this->env, $this->sandbox->ensureToStringAllowed(($context["base_path"] ?? null), 405, $this->source), "html", null, true);
        echo "safety-profile\" class=\"btn btn-secondary\">VIEW SAFETY PROFILE</a>
                        </div>
                    </div>
                </div>
            </article>
        </div>
    </div>
  </div>
</div>
<div id=\"isi\">
    <aside class=\"section\">
        <article>
            <button class=\"fixed_isi_trigger\" aria-expanded=\"false\" aria-controls=\"fixed_isi\" aria-label=\"ISI Expand Button\">
                <span></span>
            </button>
            <div class=\"isi-header\">
                <h2>Important Safety Information</h2>
            </div>
            <ul>
                <li>ENTYVIO (vedolizumab) for injection is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.</li>

                <li>Infusion-related reactions and hypersensitivity reactions including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have been reported. These reactions may occur with the first or subsequent infusions and may vary in their time of onset from during infusion or up to several hours post-infusion. If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.</li>

                <li>Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.</li>

                <li>Progressive multifocal leukoencephalopathy (PML), a rare and often fatal opportunistic infection of the central nervous system (CNS), has been reported with systemic immunosuppressants, including another integrin receptor antagonist. PML is caused by the John Cunningham (JC) virus and typically only occurs in patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with multiple contributory factors has been reported in the postmarketing setting (e.g., human immunodeficiency virus [HIV] infection with a CD4 count of 300 cells/mm<sup>3</sup> and prior and concomitant immunosuppression). Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue ENTYVIO dosing permanently.</li>

                <li>There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.</li>

                <li>Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks.</li>

                <li>Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo): nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.</li>
            </ul>

            <h2>Indications</h2>
            <h3>Adult Ulcerative Colitis (UC)</h3>
            <p>ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active UC.</p>

            <h3>Adult Crohn's Disease (CD)</h3>
            <p>ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active CD.</p>

            <p>Please see <a href=\"https://general.takedapharm.com/ENTYVIOPI\" target=\"_blank\" rel=\"noreferrer\">full Prescribing Information</a>, including <a href=\"https://general.takedapharm.com/ENTYVIOMG\" target=\"_blank\" rel=\"noreferrer\">Medication Guide</a>.</p>
        </article>
    </aside>

</div>
<div id=\"references\">
    <div class=\"section\">
        <article>
            <h3>References:</h3>

            <ol>
                <li>Entyvio (vedolizumab) prescribing information. Takeda Pharmaceuticals.</li>
                <li>Feagan BG, Rutgeerts P, Sands BE, et al; for the GEMINI 1 Study Group. <em>N Engl J Med</em>. 2013;369(8):699-710.</li>
                <li>Data on file. Takeda Pharmaceuticals.</li>
            </ol>

        </article>
    </div>
</div>
";
    }

    public function getTemplateName()
    {
        return "themes/custom/entyviohcp/templates/content/node--gemini-i-entyvio-vs-placebo--full.html.twig";
    }

    public function isTraitable()
    {
        return false;
    }

    public function getDebugInfo()
    {
        return array (  559 => 405,  548 => 397,  512 => 364,  493 => 348,  489 => 347,  485 => 346,  458 => 322,  454 => 321,  450 => 320,  419 => 292,  415 => 291,  411 => 290,  384 => 266,  380 => 265,  376 => 264,  326 => 217,  322 => 216,  318 => 215,  300 => 200,  296 => 199,  292 => 198,  265 => 174,  261 => 173,  257 => 172,  173 => 91,  169 => 90,  165 => 89,  144 => 71,  140 => 70,  136 => 69,  118 => 54,  114 => 53,  110 => 52,  79 => 24,  75 => 23,  71 => 22,  54 => 8,  50 => 7,  46 => 6,  39 => 1,);
    }

    public function getSourceContext()
    {
        return new Source("<div data-page-id=\"GeminiTrial\" data-page-category=\"ClinicalEfficacy\" class=\"page-content gemini-trial-content\" >
  <div id=\"bodyy\" class=\"article gemini-trial-article\">
    <div id=\"hero\">
      <div>
        <picture>
          <source media=\"screen and (max-width: 959px)\" srcset=\"{{ base_path ~ directory }}/images/hero/mobile-gemini-varsity-ed.png\">
          <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"{{ base_path ~ directory }}/images/hero/desktop-gemini-varsity-ed.png\">
          <img src=\"{{ base_path ~ directory }}/images/hero/desktop-gemini-varsity-ed.png\" alt=\"Patient.\">
        </picture>
        <article>
          <div>
            <h1>
              GEMINI I<br>
              <strong>UC Trials <br class=\"special-breakpoint\">I &amp; II</strong>
            </h1>
          </div>
          <div>
            <h2>Clinical <br>Response &amp; <br><strong>Long‐Term <br>Data</strong></h2>
          </div>
        </article>
        <picture>
          <source media=\"screen and (max-width: 959px)\" srcset=\"{{ base_path ~ directory }}/images/hero/mobile-gemini-i-varsity-dosing-tricia.png\">
          <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"{{ base_path ~ directory }}/images/hero/desktop-gemini-i-varsity-dosing-tricia.png\">
          <img src=\"{{ base_path ~ directory }}/images/hero/desktop-gemini-i-varsity-dosing-tricia.png\" alt=\"Healthcare professional.\">
        </picture>
      </div>
    </div>
    <div id=\"first_section\">
      <div id=\"indication_bar\" class=\"close\">
        <div>
          <div class=\"section\">
            <h3>For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough or cannot be&nbsp;tolerated.</h3>
          </div>
        </div>
      </div>
      <div>
        <article>
          <div id=\"overview-trial-data\" class=\"overview-trial-data\">
            <h2 class=\"border\">OVERVIEW OF GEMINI&nbsp;I&nbsp;DATA</h2>
            <p class=\"subheading description-below\">UC Trials I and II</p>
            <div class=\"container\">
              <div class=\"flex-container\" data-row=\"\">
                <div class=\"half graph-1\" data-col=\"mobile-12 desktop-6\">
                  <p class=\"end-point-heading\">Primary End Points</p>
                  <div class=\"tile\">
                    <h3>
                      RAPID RESPONSE AT WEEK 6 AND <nobr>LONG-TERM</nobr> REMISSION AT <br class=\"special-breakpoint-3\" data-only=\"desktop\"> WEEK&nbsp;52<sup>1</sup>
                    </h3>
                    <div class=\"image-container side-by-side gemini\">
                      <figure>
                        <picture>
                          <source media=\"screen and (max-width: 959px)\" srcset=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-clinical-remission.png\">
                          <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"{{ base_path ~ directory }}/images/charts/desktop-gemini-clinical-remission.png\">
                          <img src=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-clinical-remission.png\" alt=\"Entyvio® (vedolizumab) ulcerative colitis clinical trial rapid response and long-term remission data.\" title=\"Entyvio® GEMINI I Study Data\">
                        </picture>
                      </figure>
                    </div>
                  </div>
                </div>
                <div class=\"half graph-2 endoscopic-improvement\" data-col=\"mobile-12 desktop-6\">
                  <p class=\"end-point-heading\">Secondary End Points</p>
                  <div class=\"tile\">
                    <h3>
                        RATE OF VISIBLE MUCOSAL IMPROVEMENT AT WEEK 6 AND <br class=\"special-breakpoint-4\" data-only=\"desktop\">WEEK&nbsp;52<sup>1,2‡</sup>
                    </h3>
                    <div class=\"image-container side-by-side gemini\">
                      <figure>
                        <picture>
                          <source media=\"screen and (max-width: 959px)\" srcset=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-endoscopic-improvement.png\">
                          <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"{{ base_path ~ directory }}/images/charts/desktop-gemini-endoscopic-improvement.png\">
                          <img src=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-endoscopic-improvement.png\" alt=\"Entyvio® (vedolizumab) ulcerative colitis GEMINI I clinical trial rate of visible mucosal improvement data.\" title=\"Entyvio® GEMINI I Study Data\">
                        </picture>
                      </figure>
                    </div>
                  </div>
                </div>

                <div class=\"full text-description\">
                  <p class=\"end-point-description\"><strong>Study Design:</strong> Two randomized, double‑blind, placebo‑controlled studies enrolled adult patients with moderately to severely active UC who had failed at least 1 conventional therapy, including corticosteroids or immunomodulators and/or ≥1 anti‑TNFα therapy.<sup>1,2</sup> In UC Trial I, patients were randomized (3:2) to receive Entyvio 300&nbsp;mg or placebo by intravenous infusion at Weeks 0 and 2. In UC Trial II, patients receiving Entyvio who demonstrated clinical response at Week 6 (from UC Trial I or an open-label cohort) were randomized (1:1:1) to receive either Entyvio 300&nbsp;mg every 8&nbsp;weeks, Entyvio 300&nbsp;mg every 4&nbsp;weeks, or placebo every 4&nbsp;weeks.<sup>1</sup> The Entyvio Q4W dosing regimen did not demonstrate additional clinical benefit over the Q8W dosing regimen. The Q4W dosing regimen is not the recommended dosing regimen.</p>
                </div>

                <div class=\"half graph-3\" data-col=\"mobile-12 desktop-6\">
                  <p class=\"end-point-heading\">Secondary End Point</p>
                  <div class=\"tile last-tile\">
                    <h3>CORTICOSTEROID-FREE CLINICAL REMISSION AT WEEK&nbsp;52<sup>1,2§</sup></h3>
                    <div class=\"image-container\">
                      <figure>
                        <picture>
                          <source media=\"screen and (max-width: 959px)\" srcset=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-corticosteroid-free.png\">
                          <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"{{ base_path ~ directory }}/images/charts/desktop-gemini-corticosteroid-free.png\">
                          <img src=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-corticosteroid-free.png\" class=\"solo chart-smaller\" alt=\"Corticosteroid-free remission data in Entyvio® (vedolizumab) ulcerative colitis GEMINI I clinical trials.\" title=\"GEMINI I Study Data\">
                        </picture>
                      </figure>
                    </div>
                  </div>
                </div>
                <div class=\"half button-and-footnotes\" data-col=\"mobile-12 desktop-6\">
                  <div class=\"btn-container\">
                    <a href=\"#study-design\" class=\"btn btn-secondary\">VIEW FULL STUDY DESIGN</a>
                  </div>
                  <p class=\"footnote\">
                    <span class=\"ref\">*</span>
                    <span class=\"text\">Clinical response = reduction in complete Mayo score of ≥3 points and ≥30% from baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point.</span>
                  </p>
                  <p class=\"footnote\">
                    <span class=\"ref\"><sup>†</sup></span>
                    <span class=\"text\">Clinical remission = complete Mayo score of ≤2 points and no individual subscore&nbsp;&gt;1&nbsp;point.</span>
                  </p>
                  <p class=\"footnote\">
                    <span class=\"ref\"><sup>‡</sup></span>
                    <span class=\"text\">Improvement of endoscopic appearance of the mucosa = Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern, mild friability). </span>
                  </p>
                  <p class=\"footnote\">
                    <span class=\"ref\"><sup>§</sup></span>
                    <span class=\"text\">Assessed in the subgroup of patients who were receiving corticosteroids at baseline and who were in clinical response at Week 6 (n=72 for placebo and n=70 for Entyvio Q8W). Corticosteroid-free clinical remission was defined as the proportion of patients in this subgroup who discontinued corticosteroids by Week 52 and were in clinical remission at Week&nbsp;52.</span>
                  </p>
                  <p class=\"footnote acronyms\">
                    <span class=\"text\">CI = confidence interval; Q4W = every 4 weeks; Q8W = every 8 weeks; TNFα = tumor necrosis factor alpha.</span>
                  </p>
                </div>
              </div>
            </div>
          </div>
        </article>
      </div>
    </div>
    <div id=\"second_section\" class=\"move-ahead-header\">
      <div>
        <article>
          <div class=\"move-ahead\">
            <h2 class=\"border-center\"><span>MOVE AHEAD TO <br data-only=\"mobile\">ADDITIONAL DATA</span></h2>
            <div class=\"link-container\" data-row=\"\">
              <div data-col=\"mobile-12 desktop-4\" class=\"anchor-link-container\">
                <a href=\"#rapid-response\">Clinical Response Data</a>
              </div>
              <div data-col=\"mobile-12 desktop-4\" class=\"anchor-link-container\">
                <a href=\"#long-term-data\">Long-Term Data</a>
              </div>
              <div data-col=\"mobile-12 desktop-4\" class=\"anchor-link-container\">
                <a href=\"#study-design\">Study Design</a>
              </div>
            </div>
          </div>
        </article>
      </div>
    </div>
    <div id=\"third_section\">
        <div>
            <article>
                <div id=\"rapid-response\" class=\"clinical-response-rates\">
                    <h2 class=\"banner below-nav\"><span>CLINICAL RESPONSE DATA</span></h2>
                    <p class=\"subheading\">Clinical Response Data</p>
                    <div class=\"container\">
                        <div class=\"accordion-container\">
                            <!-- ACCORDION STARTS -->
                            <div class=\"accordion\">
                                <div class=\"accordion-list\">
                                    <ul class=\"accordion-controls\">
                                        <li class=\"active\">
                                            <div data-empty-button=\"\">
                                                ANTI‑TNFα NAÏVE <em class=\"and\">AND</em> ANTI‑TNFα FAILURE SUBPOPULATIONS
                                            </div>
                                            <p class=\"gotham-medium\">Clinical response* rates—exploratory end&nbsp;point.</p>
                                            <div id=\"clinical_response_rates_content_id_2\" aria-hidden=\"false\">
                                                <div class=\"content\">
                                                    <p class=\"link-below\">At Week 6, in the anti‑TNFα naïve subpopulation, clinical response rates were 53% for those who received Entyvio vs. 26% for those who received placebo. In the anti‑TNFα failure subpopulation, clinical response rates were 39% for those who received Entyvio vs. 21% for those who received placebo.<sup>3</sup></p>
                                                    <p data-only=\"desktop\" class=\"see-text\">Go back to top of page for GEMINI I Primary End Point Data</p>
                                                </div>
                                                <figure class=\"figure-content\">
                                                    <h3>CLINICAL RESPONSE AT WEEK&nbsp;6<sup>3</sup>*</h3>
                                                    <picture>
                                                        <source media=\"screen and (max-width: 959px)\" srcset=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-ccr-no-previous-anti-tnf-a.png\">
                                                        <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"{{ base_path ~ directory }}/images/charts/desktop-gemini-ccr-no-previous-anti-tnf-a.png\">
                                                        <img src=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-ccr-no-previous-anti-tnf-a.png\" class=\"desktop-side-padding\" alt=\"Entyvio® (vedolizumab) ulcerative colitis GEMINI I clinical trials data: response at Week 6 in Anti-TNFα naive and failure subpopulations.\" title=\"GEMINI I Study Data\">
                                                    </picture>
                                                </figure>
                                            </div>
                                        </li>
                                    </ul>
                                    <div class=\"sub-accordion-container\">
                                        <p data-only=\"mobile\" class=\"see-text jump-to\">Go back to top of page for GEMINI I Primary End Point Data</p>
                                        <div class=\"btn-container\">
                                            <a href=\"#study-design\" class=\"btn btn-secondary\">VIEW FULL STUDY DESIGN</a>
                                        </div>
                                        <p class=\"footnote\">
                                            <span class=\"ref\">*</span>
                                            <span class=\"text\">Clinical response = reduction in complete Mayo score of ≥3 points and ≥30% from baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point.</span>
                                        </p>
                                        <p class=\"footnote acronyms\">
                                            <span class=\"text\">CI = confidence interval; TNFα = tumor necrosis factor&nbsp;alpha.</span>
                                        </p>
                                    </div>
                                </div>
                                <div>
                                    <figure class=\"desktop-image\">
                                        <h3>CLINICAL RESPONSE AT WEEK&nbsp;6<sup>3</sup>*</h3>
                                        <picture>
                                            <source media=\"screen and (max-width: 959px)\" srcset=\"{{ base_path ~ directory }}images/charts/mobile-gemini-ccr-no-previous-anti-tnf-a.png\">
                                            <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"{{ base_path ~ directory }}/images/charts/desktop-gemini-ccr-no-previous-anti-tnf-a.png\">
                                            <img src=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-ccr-no-previous-anti-tnf-a.png\" class=\"desktop-side-padding\" alt=\"Entyvio® (vedolizumab) ulcerative colitis GEMINI I clinical trials data: response at Week 6 in Anti-TNFα naive and failure subpopulations.\" title=\"GEMINI I Study Data\">
                                        </picture>
                                    </figure>
                                </div>
                            </div>
                            <!-- ACCORDION ENDS -->
                        </div>
                    </div>
                    <p class=\"subheading\">Clinical Response Measured by Partial Mayo Score<sup>3</sup></p>
                    <div class=\"container\">
                        <div class=\"flex-container\" data-row=\"\">
                            <div class=\"figure-container\" data-col=\"mobile-12 desktop-7\">
                                <figure>
                                    <figcaption>CLINICAL RESPONSE RATES BASED ON PARTIAL MAYO SCORE AT WEEKS 2, 4, AND&nbsp;6<sup>3†</sup></figcaption>
                                    <picture>
                                        <source media=\"screen and (max-width: 959px)\" srcset=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-crr-partial-mayo-score.png\">
                                        <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"{{ base_path ~ directory }}/images/charts/desktop-gemini-crr-partial-mayo-score.png\">
                                        <img src=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-crr-partial-mayo-score.png\" class=\"gemini\" alt=\"Clinical response measured by partial Mayo score in Entyvio® (vedolizumab) clinical trials.\" title=\"GEMINI I Study Data\">
                                    </picture>
                                </figure>
                            </div>
                            <div class=\"copy-container gemini\" data-col=\"mobile-12 desktop-5\">
                                <p class=\"gotham-medium\">Clinical response rates based on partial Mayo&nbsp;score</p>
                                <p class=\"body-copy\">The partial Mayo score is a composite index of 3 disease activity variables (stool frequency, rectal bleeding, and physician’s global assessment), each scored on a scale from 0 to 3 (higher scores indicate greater disease activity). Partial Mayo score is calculated analogously to the complete Mayo score but excludes the sigmoidoscopy subscore.<sup>3</sup></p>
                                <p class=\"body-copy\">Clinical response was defined as a reduction in partial Mayo score of ≥2 points and ≥25% from baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point.<sup>3</sup></p>
                                <div class=\"btn-container\">
                                    <a href=\"#study-design\" class=\"btn btn-secondary gemini\">VIEW FULL STUDY DESIGN</a>
                                </div>
                                <p class=\"footnote\">
                                    <span class=\"ref\"><sup>†</sup></span>
                                    <span class=\"text\">Partial Mayo score and complete Mayo score were highly correlated at baseline and Week 6. Pearson correlation coefficients were 0.95 (95% CI: 0.94, 0.96) and 0.98 (95% CI: 0.97, 0.98) at baseline and Week 6, respectively. When further evaluating the clinical response at Week 6 correlation using kappa statistics, there was also substantial agreement between the 2 scores (0.78 [95% CI: 0.70, 0.86]). </span>
                                </p>
                                <p class=\"footnote acronyms\">
                                    <span class=\"text\">CI = confidence interval.</span>
                                </p>
                                <p class=\"bottom-text jump-to\">
                                    Go back to top of page for GEMINI I Primary End Point Data
                                </p>
                            </div>
                        </div>
                    </div>
                </div>
                <div id=\"long-term-data\" class=\"long-term-data\">
                    <h2 class=\"banner\"><span>LONG-TERM DATA</span></h2>
                    <p class=\"subheading\">Entyvio Offers Long‑Term Remission&nbsp;Data<sup>1</sup></p>
                    <div class=\"container\">
                        <div class=\"accordion-container\">
                            <!-- ACCORDION STARTS -->
                            <div class=\"accordion\">
                                <div class=\"accordion-list\">
                                    <ul class=\"accordion-controls\">
                                        <li class=\"active\">
                                            <div data-empty-button=\"\">
                                                ANTI‑TNFα NAÏVE <em class=\"and\">AND</em> ANTI‑TNFα FAILURE SUBPOPULATIONS
                                            </div>
                                            <p class=\"gotham-medium\">Long-term clinical remission* rates—exploratory end&nbsp;points.</p>
                                            <div id=\"long_term_data_content_id_2\" aria-hidden=\"false\">
                                                <div class=\"content\">
                                                    <p class=\"link-below\">At Week 52, in the anti‑TNFα naïve subpopulation, clinical remission rates were 46% for those who received Entyvio vs. 19% for those who received placebo. In the anti‑TNFα failure subpopulation, clinical remission rates were 37% for those who received Entyvio vs. 5% for those who received placebo.<sup>3</sup></p>
                                                    <p class=\"see-text\" data-only=\"desktop\">Go back to top of page for GEMINI I Primary End Point Data</p>
                                                </div>
                                                <figure class=\"figure-content\">
                                                    <h3>CLINICAL REMISSION AT WEEK&nbsp;52<sup>3</sup>*</h3>
                                                    <picture>
                                                        <source media=\"screen and (max-width: 959px)\" srcset=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-ltr-no-previous-anti-tnf-a.png\">
                                                        <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"{{ base_path ~ directory }}/images/charts/desktop-gemini-ltr-no-previous-anti-tnf-a.png\">
                                                        <img src=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-ltr-no-previous-anti-tnf-a.png\" class=\"desktop-side-padding\" alt=\"Rate of clinical remission at Week 52 Anti-TNFα subpopulations in Entyvio® (vedolizumab) GEMINI I study.\" title=\"GEMINI I Study Data\">
                                                    </picture>
                                                </figure>
                                            </div>
                                        </li>
                                    </ul>
                                    <div class=\"sub-accordion-container\">
                                        <p class=\"see-text no-margin\" data-only=\"mobile\">Go back to top of page for GEMINI I Primary End Point Data</p>
                                        <div class=\"btn-container\">
                                            <a href=\"#study-design\" class=\"btn btn-secondary\">VIEW FULL STUDY DESIGN</a>
                                        </div>
                                        <p class=\"footnote\">
                                            <span class=\"ref\">*</span>
                                            <span class=\"text\">Clinical remission = complete Mayo score of ≤2 points and no individual subscore&nbsp;&gt;1&nbsp;point.</span>
                                        </p>
                                        <p class=\"footnote acronyms\">
                                            <span class=\"text\">CI = confidence interval; Q8W = every 8 weeks; TNFα = tumor necrosis factor&nbsp;alpha.</span>
                                        </p>
                                    </div>
                                </div>
                                <div>
                                    <figure class=\"desktop-image\">
                                        <h3>CLINICAL REMISSION AT WEEK&nbsp;52<sup>3</sup>*</h3>
                                        <picture>
                                            <source media=\"screen and (max-width: 959px)\" srcset=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-ltr-no-previous-anti-tnf-a.png\">
                                            <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"{{ base_path ~ directory }}/images/charts/desktop-gemini-ltr-no-previous-anti-tnf-a.png\">
                                            <img src=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-ltr-no-previous-anti-tnf-a.png\" class=\"desktop-side-padding\" alt=\"Rate of clinical remission at Week 52 Anti-TNFα subpopulations in Entyvio® (vedolizumab) GEMINI I study.\" title=\"GEMINI I Study Data\">
                                        </picture>
                                    </figure>
                                </div>
                            </div>
                            <!-- ACCORDION ENDS -->
                        </div>
                    </div>
                    <p class=\"subheading\">Improvement of Endoscopic Appearance&nbsp;Rates<sup>1</sup></p>
                    <div class=\"container\">
                        <div class=\"accordion-container\">
                            <!-- ACCORDION STARTS -->
                            <div class=\"accordion\">
                                <div class=\"accordion-list\">
                                    <ul class=\"accordion-controls\">
                                        <li class=\"active\">
                                            <div data-empty-button=\"\">
                                                ANTI‑TNFα NAÏVE <em class=\"and\">AND</em> ANTI‑TNFα FAILURE SUBPOPULATIONS
                                            </div>
                                            <p class=\"gotham-medium\">Improvement of the endoscopic appearance of the mucosa<sup>†</sup>—exploratory end points.</p>
                                            <div id=\"double_rate_content_1\" aria-hidden=\"false\">
                                                <div class=\"content\">
                                                    <p>At Week 52, in the anti‑TNFα naïve subpopulation, improvement of the endoscopic appearance of the mucosa rates were 60% for patients who received Entyvio vs. 24% for those who received placebo. In the anti‑TNFα failure subpopulation, improvement of the endoscopic appearance of the mucosa rates were 42% for those who received Entyvio vs. 8% for those who received placebo.<sup>3</sup></p>
                                                    <p data-only=\"desktop\" class=\"see-text\">Go back to top of page for GEMINI I Primary End Point Data</p>
                                                </div>
                                                <figure class=\"figure-content\">
                                                    <h3>IMPROVEMENT OF THE APPEARANCE OF THE MUCOSA AT WEEK 52<sup>3†</sup></h3>
                                                    <picture>
                                                        <source media=\"screen and (max-width: 959px)\" srcset=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-ltr-endo-no-previous-anti-tnf-a.png\">
                                                        <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"{{ base_path ~ directory }}/images/charts/desktop-gemini-ltr-endo-no-previous-anti-tnf-a.png\">
                                                        <img src=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-ltr-endo-no-previous-anti-tnf-a.png\" alt=\"GEMINI I Entyvio® clinical trial Anti-TNFα subpopulation endoscopic subscore data.\" title=\"GEMINI I Study Data\">
                                                    </picture>
                                                </figure>
                                            </div>
                                        </li>
                                    </ul>
                                    <div class=\"sub-accordion-container\">
                                        <p data-only=\"mobile\" class=\"see-text jump-to\">Go back to top of page for GEMINI I Primary End Point Data</p>
                                        <div class=\"btn-container\">
                                            <a href=\"#study-design\" class=\"btn btn-secondary\">VIEW FULL STUDY DESIGN</a>
                                        </div>
                                        <p class=\"footnote\">
                                            <span class=\"ref\"><sup>†</sup></span>
                                            <span class=\"text\">Endoscopic improvement = Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern, mild friability).</span>
                                        </p>
                                        <p class=\"footnote acronyms\">
                                            <span class=\"text\">CI = confidence interval; Q8W = every 8 weeks; TNFα = tumor necrosis factor&nbsp;alpha.</span>
                                        </p>
                                    </div>
                                </div>
                                <div>
                                    <figure class=\"desktop-image\">
                                        <h3>IMPROVEMENT OF THE APPEARANCE OF THE MUCOSA AT WEEK 52<sup>3†</sup></h3>
                                        <picture>
                                            <source media=\"screen and (max-width: 959px)\" srcset=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-ltr-endo-no-previous-anti-tnf-a.png\">
                                            <source media=\"screen and (max-width: 9999px) and (min-width: 960px)\" srcset=\"{{ base_path ~ directory }}/images/charts/desktop-gemini-ltr-endo-no-previous-anti-tnf-a.png\">
                                            <img src=\"{{ base_path ~ directory }}/images/charts/mobile-gemini-ltr-endo-no-previous-anti-tnf-a.png\" alt=\"GEMINI I Entyvio® clinical trial Anti-TNFα subpopulation endoscopic subscore data.\" title=\"GEMINI I Study Data\">
                                        </picture>
                                    </figure>
                                </div>
                            </div>
                            <!-- ACCORDION ENDS -->
                        </div>
                    </div>
                </div>
                <div id=\"study-design\" class=\"study-design\">
                    <h2 class=\"banner\"><span>STUDY DESIGN<sup>1-3</sup></span></h2>
                    <p class=\"subheading\">GEMINI I: UC Trials I and II</p>
                    <div class=\"container\">
                        <div class=\"figure-container\">
                            <div class=\"mobile-scroll-container\">
                                <figure>
                                    <img src=\"{{ base_path ~ directory }}/images/charts/gemini-trials-study-design.png\" class=\"gemini\" alt=\"GEMINI I study design.\" title=\"GEMINI I Study Design\">
                                </figure>
                            </div>
                            <p class=\"scroll-instruction\" data-only=\"mobile\">Scroll left and right to see more</p>
                        </div>
                        <div class=\"copy-container\">
                            <ul class=\"gemini\" data-bullet=\"primary\">
                                <li>Enrolled adult patients with moderately to severely active UC who had failed at least 1 conventional therapy, including corticosteroids or immunomodulators and/or ≥1 anti‑TNFα&nbsp;therapy<sup>‡</sup></li>
                                <li><span class=\"gotham-medium\">UC Trial I:</span> 2 cohorts with primary end point evaluation at Week&nbsp;6<sup>‡</sup></li>
                                <li><span class=\"gotham-medium\">UC Trial II:</span> Patients receiving Entyvio in cohorts 1 and 2 of UC Trial I who achieved clinical response at Week 6 were randomly assigned to continue receiving Entyvio every 4 or 8 weeks, or placebo every 4&nbsp;weeks, for up to 52&nbsp;weeks<sup>‡</sup></li>
                            </ul>
                            <p class=\"footnote\">
                                <span class=\"ref\">*</span>
                                <span class=\"text\">The Entyvio Q4W dosing regimen did not demonstrate additional clinical benefit over the Q8W dosing regimen. The Q4W dosing regimen is not the recommended dosing&nbsp;regimen.</span>
                            </p>
                            <p class=\"footnote\">
                                <span class=\"ref\"><sup>†</sup></span>
                                <span class=\"text\">Clinical response = reduction in complete Mayo score of ≥3 points and ≥30% from baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1&nbsp;point.</span>
                            </p>
                            <p class=\"footnote\">
                                <span class=\"ref\"><sup>‡</sup></span>
                                <span class=\"text\">Concomitant aminosalicylates, corticosteroids, and immunomodulators were permitted. Corticosteroids were tapered after Week 6; in the United States, immunosuppressants were discontinued after&nbsp;induction.</span>
                            </p>
                            <p class=\"footnote acronyms\">
                                <span class=\"text\">IV = intravenously; Q4W = every 4 weeks; Q8W = every 8 weeks; TNFα = tumor necrosis factor alpha.</span>
                            </p>
                        </div>
                    </div>
                </div>
                <div class=\"interior-bottom-cta\">
                    <div class=\"cta-container\" data-row=\"\">
                        <div class=\"cta-1 cta\" data-col=\"mobile-12 desktop-6\">
                            <p>Entyvio vs. Humira<sup>®</sup>&nbsp;<span class=\"generic\">(adalimumab)</span> Data</p>
                            <a href=\"{{ base_path }}clinical-efficacy/ulcerative-colitis/varsity-trial\" class=\"btn btn-secondary\">SEE VARSITY STUDY RESULTS</a>
                            <p class=\"footnote\">
                                Humira<sup>®</sup> (AbbVie Inc. North Chicago, IL).<br>
                                For more information related to Humira, please see AbbVie.com.
                            </p>
                        </div>
                        <div class=\"cta-2 cta\" data-col=\"mobile-12 desktop-6\">
                            <p>Entyvio Safety Profile</p>
                            <a href=\"{{ base_path }}safety-profile\" class=\"btn btn-secondary\">VIEW SAFETY PROFILE</a>
                        </div>
                    </div>
                </div>
            </article>
        </div>
    </div>
  </div>
</div>
<div id=\"isi\">
    <aside class=\"section\">
        <article>
            <button class=\"fixed_isi_trigger\" aria-expanded=\"false\" aria-controls=\"fixed_isi\" aria-label=\"ISI Expand Button\">
                <span></span>
            </button>
            <div class=\"isi-header\">
                <h2>Important Safety Information</h2>
            </div>
            <ul>
                <li>ENTYVIO (vedolizumab) for injection is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.</li>

                <li>Infusion-related reactions and hypersensitivity reactions including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have been reported. These reactions may occur with the first or subsequent infusions and may vary in their time of onset from during infusion or up to several hours post-infusion. If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.</li>

                <li>Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.</li>

                <li>Progressive multifocal leukoencephalopathy (PML), a rare and often fatal opportunistic infection of the central nervous system (CNS), has been reported with systemic immunosuppressants, including another integrin receptor antagonist. PML is caused by the John Cunningham (JC) virus and typically only occurs in patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with multiple contributory factors has been reported in the postmarketing setting (e.g., human immunodeficiency virus [HIV] infection with a CD4 count of 300 cells/mm<sup>3</sup> and prior and concomitant immunosuppression). Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue ENTYVIO dosing permanently.</li>

                <li>There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.</li>

                <li>Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks.</li>

                <li>Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo): nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.</li>
            </ul>

            <h2>Indications</h2>
            <h3>Adult Ulcerative Colitis (UC)</h3>
            <p>ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active UC.</p>

            <h3>Adult Crohn's Disease (CD)</h3>
            <p>ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active CD.</p>

            <p>Please see <a href=\"https://general.takedapharm.com/ENTYVIOPI\" target=\"_blank\" rel=\"noreferrer\">full Prescribing Information</a>, including <a href=\"https://general.takedapharm.com/ENTYVIOMG\" target=\"_blank\" rel=\"noreferrer\">Medication Guide</a>.</p>
        </article>
    </aside>

</div>
<div id=\"references\">
    <div class=\"section\">
        <article>
            <h3>References:</h3>

            <ol>
                <li>Entyvio (vedolizumab) prescribing information. Takeda Pharmaceuticals.</li>
                <li>Feagan BG, Rutgeerts P, Sands BE, et al; for the GEMINI 1 Study Group. <em>N Engl J Med</em>. 2013;369(8):699-710.</li>
                <li>Data on file. Takeda Pharmaceuticals.</li>
            </ol>

        </article>
    </div>
</div>
", "themes/custom/entyviohcp/templates/content/node--gemini-i-entyvio-vs-placebo--full.html.twig", "C:\\xampp\\htdocs\\entyviohcp-drupal\\themes\\custom\\entyviohcp\\templates\\content\\node--gemini-i-entyvio-vs-placebo--full.html.twig");
    }
    
    public function checkSecurity()
    {
        static $tags = array();
        static $filters = array("escape" => 6);
        static $functions = array();

        try {
            $this->sandbox->checkSecurity(
                [],
                ['escape'],
                []
            );
        } catch (SecurityError $e) {
            $e->setSourceContext($this->source);

            if ($e instanceof SecurityNotAllowedTagError && isset($tags[$e->getTagName()])) {
                $e->setTemplateLine($tags[$e->getTagName()]);
            } elseif ($e instanceof SecurityNotAllowedFilterError && isset($filters[$e->getFilterName()])) {
                $e->setTemplateLine($filters[$e->getFilterName()]);
            } elseif ($e instanceof SecurityNotAllowedFunctionError && isset($functions[$e->getFunctionName()])) {
                $e->setTemplateLine($functions[$e->getFunctionName()]);
            }

            throw $e;
        }

    }
}
